AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?

The ability of AstraZeneca PLC/Daiichi Sankyo Co., Ltd.’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan) to improve response rates in heavily pre-treated patients with a range of tumor types in an open-label Phase II trial is pointing to a future for the product well beyond its current label.

Data from 267 patients presented at the American Society of Clinical Oncology meeting in Chicago on 4 June from the open-label Phase II DESTINY-PanTumor02 study in a range of HER2-expressing tumor types – biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and rare cancers – showed an ORR of 37